162 related articles for article (PubMed ID: 25470150)
1. Novel oral anticoagulants in the management of polycythemia vera and essential thrombocythemia.
Karali V; Panayiotidis P
Cardiovasc Hematol Agents Med Chem; 2014; 12(1):26-8. PubMed ID: 25470150
[TBL] [Abstract][Full Text] [Related]
2. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments.
De Stefano V; Za T; Rossi E; Vannucchi AM; Ruggeri M; Elli E; Micò C; Tieghi A; Cacciola RR; Santoro C; Gerli G; Vianelli N; Guglielmelli P; Pieri L; Scognamiglio F; Rodeghiero F; Pogliani EM; Finazzi G; Gugliotta L; Marchioli R; Leone G; Barbui T;
Haematologica; 2008 Mar; 93(3):372-80. PubMed ID: 18268279
[TBL] [Abstract][Full Text] [Related]
3. The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era.
Zhan H; Spivak JL
Clin Adv Hematol Oncol; 2009 May; 7(5):334-42. PubMed ID: 19521323
[TBL] [Abstract][Full Text] [Related]
4. Non-adherence to treatment with cytoreductive and/or antithrombotic drugs is frequent and associated with an increased risk of complications in patients with polycythemia vera or essential thrombocythemia (OUEST study).
Le Calloch R; Lacut K; Le Gall-Ianotto C; Nowak E; Abiven M; Tempescul A; Dalbies F; Eveillard JR; Ugo V; Giraudier S; Guillerm G; Lippert E; Berthou C; Ianotto JC
Haematologica; 2018 Apr; 103(4):607-613. PubMed ID: 29246923
[TBL] [Abstract][Full Text] [Related]
5. [Therapeutic effect of ranimustine (MCNU) on essential thrombocythemia and polycythemia vera].
Nagai M; Tasaka T; Kamano H; Ohnishi H; Taoka T; Ikeda K; Kubota Y; Tanaka T; Irino S
Gan To Kagaku Ryoho; 1988 Dec; 15(12):3267-70. PubMed ID: 3196045
[TBL] [Abstract][Full Text] [Related]
6. Oral anticoagulation to prevent thrombosis recurrence in polycythemia vera and essential thrombocythemia.
Hernández-Boluda JC; Arellano-Rodrigo E; Cervantes F; Alvarez-Larrán A; Gómez M; Barba P; Mata MI; González-Porras JR; Ferrer-Marín F; García-Gutiérrez V; Magro E; Moreno M; Kerguelen A; Pérez-Encinas M; Estrada N; Ayala R; Besses C; Pereira A;
Ann Hematol; 2015 Jun; 94(6):911-8. PubMed ID: 25680896
[TBL] [Abstract][Full Text] [Related]
7. Contemporary approach to essential thrombocythemia and polycythemia vera.
Aruch D; Mascarenhas J
Curr Opin Hematol; 2016 Mar; 23(2):150-60. PubMed ID: 26717193
[TBL] [Abstract][Full Text] [Related]
8. Aspirin for the control of platelet activation and prevention of thrombosis in essential thrombocythemia and polycythemia vera: current insights and rationale for future studies.
Landolfi R; Di Gennaro L; Novarese L; Patrono C
Semin Thromb Hemost; 2006 Apr; 32(3):251-9. PubMed ID: 16673279
[TBL] [Abstract][Full Text] [Related]
9. Historical perspective on the treatment of essential thrombocythemia and polycythemia vera.
Gilbert HS
Semin Hematol; 1999 Jan; 36(1 Suppl 2):19-22. PubMed ID: 9930553
[TBL] [Abstract][Full Text] [Related]
10. Treatment options for essential thrombocythemia and polycythemia vera.
Vannucchi AM; Guglielmelli P; Pieri L; Antonioli E; Bosi A
Expert Rev Hematol; 2009 Feb; 2(1):41-55. PubMed ID: 21082994
[TBL] [Abstract][Full Text] [Related]
11. 6-Thioguanine treatment for polycythemia vera and essential thrombocythemia.
Delfini C; Nicolini G; Durazzi SM; Bartolucci M; Lucarelli G
Haematologica; 1987; 72(3):273-5. PubMed ID: 3114098
[No Abstract] [Full Text] [Related]
12. Anagrelide-associated cardiomyopathy in polycythemia vera and essential thrombocythemia.
Jurgens DJ; Moreno-Aspitia A; Tefferi A
Haematologica; 2004 Nov; 89(11):1394-5. PubMed ID: 15531464
[TBL] [Abstract][Full Text] [Related]
13. Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis.
Silver RT; Kiladjian JJ; Hasselbalch HC
Expert Rev Hematol; 2013 Feb; 6(1):49-58. PubMed ID: 23373780
[TBL] [Abstract][Full Text] [Related]
14. [Chronic myeloproliferative diseases].
Sréter L
Orv Hetil; 1998 Jul; 139(30):1779-83. PubMed ID: 9718944
[TBL] [Abstract][Full Text] [Related]
15. Circulating YKL-40 in patients with essential thrombocythemia and polycythemia vera treated with the novel histone deacetylase inhibitor vorinostat.
Andersen CL; Bjørn ME; McMullin MF; Harrison C; Samuelsson J; Ejerblad E; Zweegman S; Fernandes S; Bareford D; Knapper S; Löfvenberg E; Linder O; Andreasson B; Ahlstrand E; Jensen MK; Bjerrum OW; Vestergaard H; Larsen H; Klausen TW; Mourits-Andersen T; Skov V; Thomassen M; Kruse T; Grønbæk K; Hasselbalch HC
Leuk Res; 2014 Jul; 38(7):816-21. PubMed ID: 24836761
[TBL] [Abstract][Full Text] [Related]
16. Frequent reduction or absence of detection of the JAK2-mutated clone in JAK2V617F-positive patients within the first years of hydroxyurea therapy.
Girodon F; Schaeffer C; Cleyrat C; Mounier M; Lafont I; Santos FD; Duval A; Maynadié M; Hermouet S
Haematologica; 2008 Nov; 93(11):1723-7. PubMed ID: 18728027
[TBL] [Abstract][Full Text] [Related]
17. Risk-adapted therapy in essential thrombocythemia and polycythemia vera.
Finazzi G; Barbui T
Blood Rev; 2005 Sep; 19(5):243-52. PubMed ID: 15963833
[TBL] [Abstract][Full Text] [Related]
18. New drugs in essential thrombocythemia and polycythemia vera.
Tefferi A; Elliott MA; Solberg LA; Silverstein MN
Blood Rev; 1997 Mar; 11(1):1-7. PubMed ID: 9218101
[TBL] [Abstract][Full Text] [Related]
19. Low-dose aspirin in polycythemia vera.
Dutrillaux F; Maynadié M; Carli PM
N Engl J Med; 2004 Apr; 350(16):1683-5; author reply 1683-5. PubMed ID: 15088322
[No Abstract] [Full Text] [Related]
20. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
Iványi JL; Marton E; Plander M
Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
